Pfizer Reports Q3 2026 Earnings, Raises Full-Year Guidance, Appoints New CFO

Summary of Filing

Pfizer Inc. filed a Current Report on Form 8-K under Item 2.02 (Results of Operations and Financial Condition) announcing its third-quarter 2026 financial results, an updated 2026 full-year outlook, and executive leadership updates.

Key Financial Highlights

• Q3 2026 Revenues: $16.583 billion (down marginally from $16.654 billion in Q3 2025; operational non-COVID product growth of 7%).
• Diluted EPS: Reported Diluted EPS of $0.56; Adjusted Diluted EPS of $0.87 (flat compared to prior-year period).
• Nine-Month Performance: Total revenues reached $46.067 billion (+2% YoY), with Reported Net Income of $5.681 billion and Adjusted Diluted EPS of $2.39.
• Capital Allocation: Paid $7.3 billion in cash dividends ($1.29 per share) during the first nine months; $3.3 billion remains under the share repurchase authorization with no share repurchases completed in 2026.

Raised Full-Year 2026 Guidance

• Revenues: Raised by $1.5 billion at the midpoint to $62.0 to $64.0 billion (previously $60.5 to $62.5 billion).
• Adjusted Diluted EPS: Raised and narrowed to $2.95 to $3.05 (previously $2.80 to $3.00), absorbing a $650 million (~$0.10 EPS) acquired in-process R&D charge associated with Innovent Biologics, Inc.
• Adjusted R&D Expenses: Updated to $10.8 to $11.8 billion (previously $10.5 to $11.5 billion).
• Adjusted SI&A Expenses: Reaffirmed at $12.5 to $13.5 billion.

Executive Leadership Appointment

• Cecile Guegan has been appointed as Chief Financial Officer and Executive Vice President of Pfizer Inc.